Association between novel glucose-lowering drugs and risk of asthma: A network meta-analysis of cardiorenal outcome trials
Diabetes Research and Clinical Practice — Wang A, Tang H, Zhang N, et al. | October 07, 2021
Findings indicate a likely protective effect of sodium-glucose co-transporter (SGLT) 2 inhibitors against development of asthma while there was no significant impact of dipeptidyl peptidase (DPP)-4 inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1RAs) on the asthma incident.
This is a network meta-analysis of relevant placebo-controlled cardiovascular (or cardiorenal) outcome trials that were identified from electronic databases.
A total of 19 trials comprising 218 asthma cases among 159,705 patients were included.
Relative to placebo, a significant link of SGLT2 inhibitors with a reduced risk of asthma was evident (odds ratio: OR, 0.59) while both DPP-4 inhibitors and GLP-1RAs did not significantly impact asthma risk.
SGLT2 inhibitors, compared with DPP-4 inhibitors, were significantly related to a lower risk of asthma (OR, 0.38).